Is the Oncotype DX assay included in guidelines?
Both ASCO® (American Society of Clinical Oncology®) and NCCN® (National Comprehensive Cancer Network®) have included the Oncotype DX assay in their guidelines as an option to help determine whether patients with node-negative, estrogen-receptor-positive breast cancer will benefit from chemotherapy. American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product of therapy.